A practical reference on synaptogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-01. Anything still debated is marked as such rather than presented as settled.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
== Author == Fascia: The Tensional Network of the Human Body: The science and clinical applications in manual and movement therapy. Elsevier Health Sciences. 26 February 2013. ISBN 978-0-7020-5228-6. Fascia in Sport and Movement. Handspring. 2015. ISBN 978-1-909141-07-0. Fascial Fitness: How to be Vital, Elastic and Dynamic in Everyday Life and Sport. Lotus. 2017. ISBN 978-1-905367-71-9. Fascia: The Tensional Network of the Human Body Expert Consult: Fascia: The Tensional Network of the Human Body - E-Book. Elsevier Health Sciences. 8 December 2021. ISBN 978-0-7020-8413-3. Fascial Fitness, Second Edition: Practical Exercises to Stay Flexible, Active and Pain Free in Just 20 Minutes a Week. North Atlantic Books. 6 July 2021. ISBN 978-1-62317-675-4. Fascia in Sport and Movement, Second edition. Jessica Kingsley Publishers. 30 March 2021. ISBN 978-1-912085-78-1. Der Faszien-Code: Wie die Genetik des Bindegewebes deine Gesundheit beeinflusst und du typgerecht trainierst, um Beweglichkeit und Fitness zu optimieren. Riva Verlag. 18 February 2024. ISBN 978-3-7453-2298-9.
Several studies have quantified the amounts of hallucinogenic compounds found in the fruit bodies of Psilocybe semilanceata. In 1993, Gartz reported an average of 1% psilocybin (expressed as a percentage of the dry weight of the fruit bodies), ranging from a minimum of 0.2% to a maximum of 2.37% making it one of the most potent species (but significantly less potent than panaeolus cyanescens). In an earlier analysis, Tjakko Stijve and Thom Kuyper (1985) found a high concentration in a single specimen (1.7%) in addition to a relatively high concentration of baeocystin (0.36%). Smaller specimens tend to have the highest percent concentrations of psilocybin, but the absolute amount is highest in larger mushrooms. A Finnish study assayed psilocybin concentrations in old herbarium specimens, and concluded that although psilocybin concentration decreased linearly over time, it was relatively stable. They were able to detect the chemical in specimens that were 115 years old. Michael Beug and Jeremy Bigwood, analyzing specimens from the Pacific Northwest region of the United States, reported psilocybin concentrations ranging from 0.62% to 1.28%, averaging 1.0 ±0.2%. They concluded that the species was one of the most potent, as well as the most constant in psilocybin levels. In a 1996 publication, Paul Stamets defined a "potency rating scale" based on the total content of psychoactive compounds (including psilocybin, psilocin, and baeocystin) in 12 species of Psilocybe mushrooms.
Since 2021, China has faced a property sector crisis, with decreasing house prices, shrinking of the real estate sector and bankruptcies of many property developers, partially as a result of Xi's efforts to decrease the sector's role in the Chinese economy. Xi has heavily emphasized the role of advanced manufacturing and technology development to drive China's future economic growth. Since shortly after taking office as General Secretary, Xi emphasised the use of industrial policy to increase domestic innovation and reduce reliance on foreign technology. In 2015, Xi's administration launched the Double First-Class Construction, a higher education development and sponsorship scheme intended to replace the previous programs Project 211 and Project 985. Xi's administration has promoted Made in China 2025 plan that aims to make China self-reliant in key technologies; although publicly China de-emphasised this plan due to the outbreak of a China–United States trade war, majority of its goals were considered achieved by 2024. Since the outbreak of the trade war in 2018, Xi has further pushed calls for "self-reliance", especially on technology. China's domestic spending on R&D has significantly increased, surpassing the European Union (EU) and reaching a record $564 billion in 2020. The Chinese government has supported technology companies like Huawei through grants, tax breaks, credit facilities and other assistance, enabling their rise, leading to US countermeasures.
== Utility and benefits == Most countries currently strive to implement eHealth systems for electronic management and communication of healthcare information. The primary drivers for adoption of Electronic Health Records (EHR) and supporting infrastructure include:
Sources: en.wikipedia.org
=== Tyrannosaurus imperator and Tyrannosaurus regina === In a 2022 study, Gregory S. Paul and colleagues argued that Tyrannosaurus rex, as traditionally understood, actually represents three species: the type species Tyrannosaurus rex, and two previously unrecognized species: T. imperator (meaning "tyrant lizard emperor") and T. regina (meaning "tyrant lizard queen"). The holotype of the former (T. imperator) is the Sue specimen, and the holotype of the latter (T. regina) is Wankel rex. The division into multiple species was primarily based on the high degree of variation in the proportions and robusticity of the femur (and other skeletal elements) across T. rex specimens. Presumed robust and gracile morphotypes and the number of small incisiform teeth in the dentary were also used as a line of evidence. Paul and colleagues categorized the species as follows: T. rex demonstrates robust anatomy, a moderate ratio of femur length vs circumference, and the possession of a singular slender incisiform dentary tooth, T. imperator is robust with a small femur length to circumference ratio and two of the slender teeth, and T. regina is more gracile with a high femur ratio and one of the slender teeth. However, several leading paleontologists, including Stephen Brusatte, Thomas Carr, Thomas Holtz, David Hone, Jingmai O'Connor, and Lindsay Zanno, criticized the study or expressed skepticism of its conclusions.
While the review in the JB&JS was able to correlate receiving rodding surgery with greater mobility across all types of OI, in patients with type IV, the surgery did not decrease the incidence of broken bones as compared to non-rodded patients—while type IV patients with rodded tibiae experienced 0.93 tibia fractures per year, patients with natural tibiae experienced only 0.81. However, in patients with type III, rodding surgery decreased the average number of tibia fractures per year from 0.84 to 0.57.
=== U.S. production ceases and resumes === The United States stopped producing bulk 238Pu with the closure of the Savannah River Site reactors in 1988. Since 1993, all of the 238Pu used in American spacecraft has been purchased from Russia. From 1992 to 1994, 10 kilograms were purchased by the US Department of Energy from Russia's Mayak Production Association. Via agreement with Minatom, the US must use plutonium for uncrewed NASA missions, and Russia must use the currency for environmental and social investment in the Chelyabinsk region, affected by long-term radioactive contamination such as the Kyshtym disaster. In total, 16.5 kilograms (36 lb) have been purchased, but Russia is no longer producing 238Pu, and their own supply is reportedly running low. In February 2013, a small amount of 238Pu was successfully produced by Oak Ridge's High Flux Isotope Reactor, and on December 22, 2015, they reported the production of 50 grams (1.8 ounces) of 238Pu. In March 2017, Ontario Power Generation (OPG) and its venture arm, Canadian Nuclear Partners, announced plans to produce 238Pu as a second source for NASA. Rods containing neptunium-237 will be fabricated by Pacific Northwest National Laboratory (PNNL) in Washington State and shipped to OPG's Darlington Nuclear Generating Station in Clarington, Ontario, Canada where they will be irradiated with neutrons inside the reactor's core to produce 238Pu.
Sources: en.wikipedia.org
The main use of calcium sulfate is to produce plaster of Paris and stucco. These applications exploit the fact that calcium sulfate which has been powdered and calcined forms a moldable paste upon hydration and hardens as crystalline calcium sulfate dihydrate. It is also convenient that calcium sulfate is poorly soluble in water and does not readily dissolve in contact with water after its solidification.
=== Bellido cabinet === The Bellido Cabinet, made by Castillo, was widely criticized in the media and from various political opponents of the new government. Some journalists, like Fernando Vivas from El Comercio, called it the "shock cabinet," due to the belief that it was meant to bait Congress into denying confidence twice so that Congress could be shut down, as it was during the 2019–2020 Peruvian constitutional crisis. A congressman from Free Peru claimed that Congress was attempting to impeach Castillo, and warned that if trust is denied twice then Congress will be dissolved. Vice President Dina Boluarte said that Congress would not be dissolved. The cabinet led to the Purple Party and We Are Peru leaving the government coalition, and sparked backlash from Congress and sectors of the public. President Pedro Castillo appointed the new head of the Joint Command of the Armed Forces (CC. FF. AA.); on 3 August, Manuel Gómez de la Torre replaced General César Astudillo as General Commander. Changes were also made for the general commanders of the Army, Navy, and Air Force. On 6 October 2021, President Castillo announced the resignation of the Guido Bellido cabinet, citing instability in the country. Under Peruvian law, the resignation of the Prime Minister dissolves the cabinet. A new cabinet was formed, led by Mirtha Vásquez.
== Chemical properties == At physiological pH, the ε-amino group (–NH2) of the lysine residue exists almost entirely in its protonated form (–NH3+), whereas the carboxyl group (–COOH) of the malonyl group exists almost entirely in its deprotonated form (–COO-). Through the covalent attachment of a malonyl group to the ε-amino group, the lysine residue loses its positive charge and assumes the negative charge of the malonyl group, resulting in a charge shift from +1 to −1. This complete reversal of charge is thought to disrupt ionic interactions both within the protein itself and with negatively charged components of nucleotides, proteins and small molecules. Such alterations can occur at multiple lysine residues within a single protein, although their overall frequency varies considerably across the proteome. In mouse liver, for example, about half of all malonylated proteins contain a single site, while the frequency decreases sharply beyond four sites and only a few are extensively modified, the most heavily modified enzyme being carbamoyl‑phosphate synthetase 1 (CPS1) of the urea cycle with 31 sites. In the context of other lysine acylations, malonylation can be positioned as follows: While acetylation neutralizes lysine's positive charge, malonylation introduces a negative one, placing it among the acidic acylations alongside methylmalonylation, succinylation, glutarylation, 3‑hydroxy‑3‑methylglutarylation, 3‑methylglutaconylation, and 3‑methylglutarylation.
The DSM-5 guidelines for the diagnosis of opioid use disorder require that the individual has a significant impairment or distress related to opioid uses. To make the diagnosis two or more of 11 criteria must be present in a given year:
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.